Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

The Danish pharma giant tested monlunabant, a drug it acquired in 2023 with its $1 billion purchase of Inversago Pharma, in a phase 2 trial involving 243 participants with obesity and other ...

“We are encouraged to see that monlunabant met its primary endpoint and demonstrated at least a 6% placebo-adjusted weight loss at 16 weeks, which we see as broadly supportive of the mechanism ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to ...

Earlier on Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist.

Yet their accumulation in the brain induced neuropsychiatric adverse events, serious in the case of rimonabant, mild to moderate in the recently reported case of monlunabant, and these small ...

“We are encouraged to see that monlunabant met its primary endpoint and demonstrated at least a 6% placebo-adjusted weight loss at 16 weeks, which we see as broadly supportive of the mechanism of ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean mice Dose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight loss in DIO mice Semaglutide treatment ...

Key findings: CRB-913 brain levels were 15-fold lower than monlunabant at the same dose in mice. Plasma-to-brain ratio for CRB-913 was 10 times higher than monlunabant and 50 times higher than ...